



S5 Fig. Survival analysis of progression-free survival of all patients (A), stage I/II (B), and stage III/IV (C), as well as overall survival of all patients (D), stage I/II (E), and stage III/IV(F). IMEP+L/P, ifosfamide, mesna, etoposide, prednisolone+L-asparaginase/peg-asparaginase; HR, hazard ratio; CI, confidence interval.